390 related articles for article (PubMed ID: 33572999)
1. Cancer-Targeted Controlled Delivery of Chemotherapeutic Anthracycline Derivatives Using Apoferritin Nanocage Carriers.
Kurzątkowska K; Pazos MA; Herschkowitz JI; Hepel M
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33572999
[TBL] [Abstract][Full Text] [Related]
2. Apoferritin Nanocage for Brain Targeted Doxorubicin Delivery.
Chen Z; Zhai M; Xie X; Zhang Y; Ma S; Li Z; Yu F; Zhao B; Zhang M; Yang Y; Mei X
Mol Pharm; 2017 Sep; 14(9):3087-3097. PubMed ID: 28728419
[TBL] [Abstract][Full Text] [Related]
3. Spectroscopic and cytotoxicity studies on the combined interaction of (-)-epigallocatechin-3-gallate and anthracycline drugs with human serum albumin.
Guo Q; Liu M; Zhao Y; Wu Y; Liu J; Cai C; Shi Y; Han J
Spectrochim Acta A Mol Biomol Spectrosc; 2019 Nov; 222():117213. PubMed ID: 31177010
[TBL] [Abstract][Full Text] [Related]
4. A novel protein-based anticancer drug encapsulating nanosphere: apoferritin-doxorubicin complex.
Kilic MA; Ozlu E; Calis S
J Biomed Nanotechnol; 2012 Jun; 8(3):508-14. PubMed ID: 22764421
[TBL] [Abstract][Full Text] [Related]
5. Nanoparticle-Modified Apoferritin Nanotransfer for Targeted Cytostatic Transport.
Čížek M; Gargulák M; Sehnal K; Uhlířová D; Staňková M; Dočekalová M; Ruttkay-Nedecký B; Zídková J; Kizek R
Klin Onkol; 2019; 32(3):197-200. PubMed ID: 31216851
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the interaction of doxorubicin, daunorubicin, idarubicin and idarubicinol with large unilamellar vesicles. Circular dichroism study.
Gallois L; Fiallo M; Garnier-Suillerot A
Biochim Biophys Acta; 1998 Mar; 1370(1):31-40. PubMed ID: 9518541
[TBL] [Abstract][Full Text] [Related]
7. High payload and targeted release of anthracyclines by aptamer-tethered DNA nanotrains - Thermodynamic and release kinetic study.
Pei W; Liu M; Wu Y; Zhao Y; Liu T; Sun B; Liu Y; Wang Q; Han J
Eur J Pharm Sci; 2020 May; 148():105319. PubMed ID: 32205231
[TBL] [Abstract][Full Text] [Related]
8. Electrochemical, spectroscopic and theoretical monitoring of anthracyclines' interactions with DNA and ascorbic acid by adopting two routes: Cancer cell line studies.
Perveen F; Arshad N; Qureshi R; Nowsherwan J; Sultan A; Nosheen B; Rafique H
PLoS One; 2018; 13(10):e0205764. PubMed ID: 30372448
[TBL] [Abstract][Full Text] [Related]
9. Ofloxacin@Doxorubicin-Epirubicin functionalized MCM-41 mesoporous silica-based nanocarriers as synergistic drug delivery tools for cancer related bacterial infections.
Galhano J; Marcelo GA; Duarte MP; Oliveira E
Bioorg Chem; 2022 Jan; 118():105470. PubMed ID: 34814085
[TBL] [Abstract][Full Text] [Related]
10. Nuclear targeting and nuclear retention of anthracycline-formaldehyde conjugates implicates DNA covalent bonding in the cytotoxic mechanism of anthracyclines.
Taatjes DJ; Fenick DJ; Koch TH
Chem Res Toxicol; 1999 Jul; 12(7):588-96. PubMed ID: 10409398
[TBL] [Abstract][Full Text] [Related]
11. Smart thermo/pH responsive magnetic nanogels for the simultaneous delivery of doxorubicin and methotrexate.
Salehi R; Rasouli S; Hamishehkar H
Int J Pharm; 2015 Jun; 487(1-2):274-84. PubMed ID: 25895723
[TBL] [Abstract][Full Text] [Related]
12. Oxidized phospholipid based pH sensitive micelles for delivery of anthracyclines to resistant leukemia cells in vitro.
Wang Y; Chen L; Ding Y; Yan W
Int J Pharm; 2012 Jan; 422(1-2):409-17. PubMed ID: 22037443
[TBL] [Abstract][Full Text] [Related]
13. Cyclodextrin derivatives conjugated with aromatic moieties as pH-responsive drug carriers for anthracycline.
Swiech O; Dutkiewicz P; Wójciuk K; Chmurski K; Kruszewski M; Bilewicz R
J Phys Chem B; 2013 Oct; 117(43):13444-50. PubMed ID: 24079546
[TBL] [Abstract][Full Text] [Related]
14. Site-Directed Conjugation of Antibodies to Apoferritin Nanocarrier for Targeted Drug Delivery to Prostate Cancer Cells.
Dostalova S; Cerna T; Hynek D; Koudelkova Z; Vaculovic T; Kopel P; Hrabeta J; Heger Z; Vaculovicova M; Eckschlager T; Stiborova M; Adam V
ACS Appl Mater Interfaces; 2016 Jun; 8(23):14430-41. PubMed ID: 27219717
[TBL] [Abstract][Full Text] [Related]
15. Development and characterization of folic acid-functionalized apoferritin as a delivery vehicle for epirubicin against MCF-7 breast cancer cells.
Gomhor J Alqaraghuli H; Kashanian S; Rafipour R; Mahdavian E; Mansouri K
Artif Cells Nanomed Biotechnol; 2018; 46(sup3):S847-S854. PubMed ID: 30449179
[TBL] [Abstract][Full Text] [Related]
16. A pH-sensitive DNA tetrahedron for targeted release of anthracyclines: Binding properties investigation and cytotoxicity evaluation.
Weng T; Wang L; Zhang X; Wu Y; Zhao Y; Zhang Y; Han J; Liu M
Int J Biol Macromol; 2022 Dec; 223(Pt A):766-778. PubMed ID: 36372106
[TBL] [Abstract][Full Text] [Related]
17. Stability and compatibility of four anthracyclines: doxorubicin, epirubicin, daunorubicin and pirarubicin with PVC infusion bags.
Dine T; Cazin JC; Gressier B; Luyckx M; Brunet C; Cazin M; Goudaliez F; Mallevais ML; Toraub I
Pharm Weekbl Sci; 1992 Dec; 14(6):365-9. PubMed ID: 1475177
[TBL] [Abstract][Full Text] [Related]
18. Apoferritin as an ubiquitous nanocarrier with excellent shelf life.
Dostalova S; Vasickova K; Hynek D; Krizkova S; Richtera L; Vaculovicova M; Eckschlager T; Stiborova M; Heger Z; Adam V
Int J Nanomedicine; 2017; 12():2265-2278. PubMed ID: 28392686
[TBL] [Abstract][Full Text] [Related]
19. Modulation of induced cytotoxicity of doxorubicin by using apoferritin and liposomal cages.
Gumulec J; Fojtu M; Raudenska M; Sztalmachova M; Skotakova A; Vlachova J; Skalickova S; Nejdl L; Kopel P; Knopfova L; Adam V; Kizek R; Stiborova M; Babula P; Masarik M
Int J Mol Sci; 2014 Dec; 15(12):22960-77. PubMed ID: 25514405
[TBL] [Abstract][Full Text] [Related]
20. Influence of the structure of new anthracycline antibiotics on their biological properties.
Wasowska M; Oszczapowicz I; Wietrzyk J; Opolski A; Madej J; Dzimira S; Oszczapowicz J
Anticancer Res; 2005; 25(3B):2043-8. PubMed ID: 16158943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
